CPI-0610

DRUG4 trials

Sponsors

Novartis Pharma AG, Constellation Pharmaceuticals, University of Texas Southwestern Medical Center

Conditions

LymphomaMultiple MyelomaMyelofibrosisMyeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)Peripheral Nerve Tumors

Phase 1

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

CompletedNCT01949883

Constellation PharmaceuticalsLymphoma

Start: 2013-09-05End: 2017-12-20Updated: 2024-05-08

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

CompletedNCT02157636

Constellation PharmaceuticalsMultiple Myeloma

Start: 2014-07-15End: 2016-11-08Updated: 2024-04-18

Phase 2

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

WithdrawnNCT02986919

University of Texas Southwestern Medical CenterPeripheral Nerve Tumors

Start: 2017-05-05End: 2018-05-17Updated: 2018-09-11

Phase 3

An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

RecruitingCTIS2023-508950-24-00

Novartis Pharma AGMyelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

Start: 2024-10-01Target: 34Updated: 2026-01-26

Related Papers

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

Cancer Research Communications2022-07-1533 citations

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Blood2021-11-053 citations

Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma

Cancer Research2018-07-012 citations

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Oncotarget2016-12-0792 citations

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Blood2016-12-022 citations